186 related articles for article (PubMed ID: 30805052)
1. Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): Three-month interim analysis results.
Yamashita T; Koretsune Y; Ishikawa M; Shiosakai K; Kogure S
J Arrhythm; 2019 Feb; 35(1):121-129. PubMed ID: 30805052
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): One-year safety and effectiveness analyses.
Yamashita T; Koretsune Y; Nagao T; Shiosakai K
J Arrhythm; 2020 Jun; 36(3):395-405. PubMed ID: 32528563
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two-year postmarketing surveillance study (ETNA-AF-Japan).
Yamashita T; Koretsune Y; Nagao T; Shiosakai K
J Arrhythm; 2021 Apr; 37(2):370-383. PubMed ID: 33850579
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data.
Monteiro P
Rev Port Cardiol (Engl Ed); 2020 Nov; 39(11):651-662. PubMed ID: 33190965
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
[TBL] [Abstract][Full Text] [Related]
6. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
[TBL] [Abstract][Full Text] [Related]
7. Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub-Analysis of the ELDERCARE-AF Trial.
Mikami T; Hirabayashi K; Okawa K; Betsuyaku T; Watanabe S; Imamura Y; Tanizawa K; Hayashi T; Akao M; Yamashita T; Okumura K
J Am Heart Assoc; 2022 Sep; 11(17):e024970. PubMed ID: 36056729
[TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program.
De Caterina R; Kim YH; Koretsune Y; Wang CC; Yamashita T; Chen C; Reimitz PE; Unverdorben M; Kirchhof P
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33546442
[TBL] [Abstract][Full Text] [Related]
9. Edoxaban treatment in atrial fibrillation in routine clinical care: One-year outcomes of the prospective observational ETNA-AF study in South Korean patients.
Choi EK; Choi JI; Park HS; Hwang GS; Joung B; Kim JY; Kim DH; Shin DG; Park HW
J Arrhythm; 2023 Aug; 39(4):546-555. PubMed ID: 37560283
[TBL] [Abstract][Full Text] [Related]
10. The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.
De Caterina R; Agnelli G; Laeis P; Unverdorben M; Rauer H; Wang CC; Nakamura M; Chiu KM; Reimitz PE; Koretsune Y; Chen C; Thee U; Kaburagi J; Kim YH; Choi WI; Yamashita T; Cohen A; Kirchhof P
Clin Cardiol; 2019 Dec; 42(12):1147-1154. PubMed ID: 31650560
[TBL] [Abstract][Full Text] [Related]
11. Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care.
Kirchhof P; Pecen L; Bakhai A; de Asmundis C; de Groot JR; Deharo JC; Kelly P; Levy P; Lopez-de-Sa E; Monteiro P; Steffel J; Waltenberger J; Weiss TW; Laeis P; Manu MC; Souza J; De Caterina R
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):47-57. PubMed ID: 35881467
[TBL] [Abstract][Full Text] [Related]
12. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.
de Groot JR; Weiss TW; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Waltenberger J; Steffel J; Levy P; Bakhai A; Zierhut W; Laeis P; Manu MC; Reimitz PE; De Caterina R; Kirchhof P
Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f30-f39. PubMed ID: 32790837
[TBL] [Abstract][Full Text] [Related]
13. Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry.
Gwechenberger M; Barón-Esquivias G; de Vries TAC; Siller-Matula JM; Manu MC; Souza JAG; Wienerroither S; Pecen L; de Groot JR; De Caterina R; Kirchhof P;
JACC Adv; 2024 Apr; 3(4):100880. PubMed ID: 38939675
[TBL] [Abstract][Full Text] [Related]
14. Safety and Effectiveness of Edoxaban in Japanese Patients With Venous Thromboembolism - An Interim Analysis of Data From a Japanese Postmarketing Observational Study (ETNA-VTE-Japan).
Nakamura M; Yamada N; Asamura T; Shiosakai K; Uchino K
Circ J; 2019 May; 83(6):1394-1404. PubMed ID: 31080193
[TBL] [Abstract][Full Text] [Related]
15. Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation Patients From Asia - One-Year Data From the Global ETNA-AF Program.
Choi JI; Kiatchoosakun S; Jiampo P; Tse HF; Soo YOY; Wang CC; Lee CH; Pecen L; Unverdorben M; De Caterina R; Kirchhof P
Circ Rep; 2024 Mar; 6(3):86-93. PubMed ID: 38464984
[No Abstract] [Full Text] [Related]
16. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
Okumura K; Lip GYH; Akao M; Tanizawa K; Fukuzawa M; Abe K; Akishita M; Yamashita T
Am Heart J; 2017 Dec; 194():99-106. PubMed ID: 29223441
[TBL] [Abstract][Full Text] [Related]
17. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey Study: Design and Rationale.
Önsel Türk U; Alioğlu E; Mavioğlu Z; Diker E; Özpelit E; De Caterina R
Turk Kardiyol Dern Ars; 2022 Mar; 50(2):117-123. PubMed ID: 35400633
[TBL] [Abstract][Full Text] [Related]
19. Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice.
Choi EK; Lin WS; Hwang GS; Kirchhof P; De Caterina R; Chen C; Unverdorben M; Wang CC; Kim YH
J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830618
[TBL] [Abstract][Full Text] [Related]
20. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
